← Back to Screener
ALX Oncology Holdings Inc. Common Stock (ALXO)
Price$1.68
Favorite Metrics
Price vs S&P 500 (26W)-18.71%
Price vs S&P 500 (4W)-27.68%
Market Capitalization$221.10M
All Metrics
Book Value / Share (Quarterly)$0.48
P/TBV (Annual)1.67x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.55
Price vs S&P 500 (YTD)46.03%
Gross Margin (TTM)9.02%
Net Profit Margin (TTM)-753.55%
EPS (TTM)$-1.90
10-Day Avg Trading Volume1.22M
EPS Excl Extra (TTM)$-1.90
EPS (Annual)$-2.60
ROI (Annual)-106.30%
Gross Margin (Annual)9.32%
Cash / Share (Quarterly)$0.82
ROA (Last FY)-91.22%
EBITD / Share (TTM)$-1.93
ROE (5Y Avg)-56.73%
Operating Margin (TTM)-731.97%
Cash Flow / Share (Annual)$-2.31
P/B Ratio8.51x
P/B Ratio (Quarterly)2.36x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-8347.00x
ROA (TTM)-113.63%
EPS Incl Extra (Annual)$-2.60
Current Ratio (Annual)7.05x
Quick Ratio (Quarterly)1.87x
3-Month Avg Trading Volume0.64M
52-Week Price Return235.13%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.10
P/S Ratio (Annual)187.37x
Asset Turnover (Annual)0.00x
52-Week High$2.66
EPS Excl Extra (Annual)$-2.60
CapEx CAGR (5Y)47.86%
26-Week Price Return-14.72%
Quick Ratio (Annual)6.78x
13-Week Price Return16.67%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)2.07x
Enterprise Value$216.037
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3855.93%
Cash / Share (Annual)$2.42
3-Month Return Std Dev98.31%
Net Income / Employee (TTM)$-2
ROE (Last FY)-118.42%
Net Interest Coverage (Annual)-54.49x
EPS Basic Excl Extra (Annual)$-2.60
Total Debt / Equity (Quarterly)0.44x
EPS Incl Extra (TTM)$-1.90
ROI (TTM)-149.92%
P/S Ratio (TTM)60.41x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.45
Price vs S&P 500 (52W)205.30%
Year-to-Date Return48.67%
5-Day Price Return-1.18%
EPS Normalized (Annual)$-2.60
ROA (5Y Avg)-46.04%
Net Profit Margin (Annual)-3876.27%
Month-to-Date Return-16.21%
Cash Flow / Share (TTM)$-3.54
EBITD / Share (Annual)$-2.58
Operating Margin (Annual)-3752.54%
LT Debt / Equity (Annual)0.05x
ROI (5Y Avg)-52.96%
LT Debt / Equity (Quarterly)0.17x
EPS Basic Excl Extra (TTM)$-1.90
P/TBV (Quarterly)2.61x
P/B Ratio (Annual)0.77x
Pretax Margin (TTM)-753.01%
Book Value / Share (Annual)$2.15
Price vs S&P 500 (13W)15.98%
Beta0.46x
Revenue / Share (TTM)$0.00
ROE (TTM)-182.01%
52-Week Low$0.40
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.08
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALXOALX Oncology Holdings Inc. Common Stock | 60.41x | — | 9.02% | — | $1.68 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
ALX Oncology is a clinical-stage immuno-oncology company developing CD47-blocking therapies to enhance the immune system's ability to recognize and eliminate cancer cells. The company's lead program, evorpacept, is in phase 1 and 2 clinical trials and targets the CD47 "don't eat me" signal that allows cancer cells to evade immune detection. ALX's approach leverages protein engineering expertise to achieve high CD47 affinity while avoiding the hematologic toxicities that limit other CD47-blocking strategies.